PTCT PTC Therapeutics Inc.

29.64
-3.38  -10%
Previous Close 33.02
Open 30.22
Price To Book 3.88
Market Cap 1495481280
Shares 50,454,834
Volume 5,252,094
Short Ratio
Av. Daily Volume 730,504

SEC filingsSee all SEC filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 19535586
  2. 8-K - Current report 19512352
  3. S-8 - Securities to be offered to employees in employee benefit plans 19507176
  4. CT ORDER - Confidential treatment order 181240452
  5. 8-K - Current report 181239414

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiated October 2016. Phase 3 part of trial has commenced - noted October 12, 2017.
RG7916
Spinal Muscular Atrophy (SMA)
Received a Refusal to File letter February 23 2016. Appeal rejected October 17, 2016. Decision made to resubmit NDA during 1Q 2017 under protest. Further CRL October 25, 2017. Expects to initiate new trial by the end of 2018.
Ataluren
Duchenne muscular dystrophy caused by nonsense mutations (nmDMD)
FDA Approval announced October 5, 2018,
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Phase 3 data released March 2, 2017 - endpoints not met. Development to be discontinued.
Translarna
Nonsense mutation cystic fibrosis
Noted March 15, 2018 that trial has transitioned into pivotal phase. Updated positive Phase 1 data released June 16, 2018.
RG7916 - FIREFISH
Spinal Muscular Atrophy (SMA) Type 1

Latest News

  1. Why Capital One Financial, PTC Therapeutics, and Quotient Technology Slumped Today
  2. Here's Why PTC Therapeutics Fell as Much as 11.7% Today
  3. PTC Therapeutics Announces Pricing of Public Offering of Common Stock
  4. The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoporosis Drug Study
  5. PTC Therapeutics Announces Proposed Public Offering of Common Stock
  6. PTC Therapeutics Announces Executive Team Updates Focused on Accelerating Pipeline and Bringing Gene Therapy Manufacturing In-house
  7. PTC Therapeutics Provides Corporate Update and Outlines 5-year Strategic Plan at 2019 J.P. Morgan Healthcare Conference
  8. Praesidium Investment Management’s Return, AUM, and Holdings
  9. PTC Therapeutics to Participate at Upcoming Investor Conference
  10. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  11. PTC Therapeutics Deepens Financial and Commercial Expertise of Board with Two New Appointments
  12. Roche's SMA Candidate Risdiplam Gets PRIME Designation in EU
  13. Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
  14. Is PTC Therapeutics, Inc.’s (NASDAQ:PTCT) CEO Paid Enough Relative To Peers?
  15. Ghost Tree Capital’s AUM, Returns and Holdings
  16. Hedge Funds Are Buying PTC Therapeutics, Inc. (PTCT)
  17. Edited Transcript of PTCT earnings conference call or presentation 5-Nov-18 9:30pm GMT

SEC Filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 19535586
  2. 8-K - Current report 19512352
  3. S-8 - Securities to be offered to employees in employee benefit plans 19507176
  4. CT ORDER - Confidential treatment order 181240452
  5. 8-K - Current report 181239414
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181160758
  7. 8-K - Current report 181160101
  8. 8-K - Current report 181111410
  9. D - Notice of Exempt Offering of Securities 181055193
  10. 8-K - Current report 181040118